User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy

Primary tabs

Walzer, Stefan Chouaid, Christos Lister, Johanna Gultyaev, Dmitry Vergnenegre, Alain Crott, Ralph [UCL] Ngoh, Charles

In recent years, the treatment landscape in advanced non-squamous non-small-cell lung cancer (nsNSCLC) has changed. New therapies (e.g., bevacizumab indicated in first line) have become available and other therapies (e.g., pemetrexed in first line and second line) moved into earlier lines in the treatment paradigm. While there has been an expansion of the available treatment options, it is still a key research question which therapy sequence results in the best survival outcomes for patients with nsNSCLC.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2015
Language Anglais
Journal information "Expert Review of Anticancer Therapy" - Vol. 15, no.1, p. 121-128 (2015)
Peer reviewed yes
Publisher Expert Reviews Ltd. (London)
issn 1473-7140
e-issn 1744-8328
Publication status Publié
Affiliation UCL - SSS/IRSS - Institut de recherche santé et société
Links
  1. Sant M., EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary, 10.1093/annonc/mdg754
  2. Ferlay J, GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide. IARC CancerBase No 10 (2008)
  3. Goldstraw Peter, Crowley John, Chansky Kari, Giroux Dorothy J., Groome Patti A., Rami-Porta Ramon, Postmus Pieter E., Rusch Valerie, Sobin Leslie, The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, 10.1097/jto.0b013e31812f3c1a
  4. American Cancer Society, Cancer facts & figures 2009 (2009)
  5. Groome Patti A., Bolejack Vanessa, Crowley John J., Kennedy Catherine, Krasnik Mark, Sobin Leslie H., Goldstraw Peter, The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, 10.1097/jto.0b013e31812d05d5
  6. Balducci L., Death and dying: what the patient wants, 10.1093/annonc/mds089
  7. , Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials, 10.1136/bmj.311.7010.899
  8. Schiller Joan H., Harrington David, Belani Chandra P., Langer Corey, Sandler Alan, Krook James, Zhu Junming, Johnson David H., Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer, 10.1056/nejmoa011954
  9. Rossi Antonio, Maione Paolo, Colantuoni Giuseppe, Ferrara Carmine, Rossi Emanuela, Guerriero Ciro, Nicolella Dario, Falanga Marzia, Palazzolo Giovanni, Gridelli Cesare, Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer, 10.2174/157016309788488339
  10. Pallis A.G., Serfass L., Dziadziuszko R., van Meerbeeck J.P., Fennell D., Lacombe D., Welch J., Gridelli C., Targeted therapies in the treatment of advanced/metastatic NSCLC, 10.1016/j.ejca.2009.06.005
  11. Scagliotti Giorgio Vittorio, Parikh Purvish, von Pawel Joachim, Biesma Bonne, Vansteenkiste Johan, Manegold Christian, Serwatowski Piotr, Gatzemeier Ulrich, Digumarti Raghunadharao, Zukin Mauro, Lee Jin S., Mellemgaard Anders, Park Keunchil, Patil Shehkar, Rolski Janusz, Goksel Tuncay, de Marinis Filippo, Simms Lorinda, Sugarman Katherine P., Gandara David, Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer, 10.1200/jco.2007.15.0375
  12. Crinò Lucio, Dansin Eric, Garrido Pilar, Griesinger Frank, Laskin Janessa, Pavlakis Nick, Stroiakovski Daniel, Thatcher Nick, Tsai Chun-Ming, Wu Yi-long, Zhou Caicun, Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study, 10.1016/s1470-2045(10)70151-0
  13. Hanna Nasser, Shepherd Frances A., Fossella Frank V., Pereira Jose R., De Marinis Filippo, von Pawel Joachim, Gatzemeier Ulrich, Tsao Thomas Chang Yao, Pless Miklos, Muller Thomas, Lim Hong-Liang, Desch Christopher, Szondy Klara, Gervais Radj, Shaharyar, Manegold Christian, Paul Sofia, Paoletti Paolo, Einhorn Lawrence, Bunn Paul A., Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy, 10.1200/jco.2004.08.163
  14. Paz-Ares Luis, de Marinis Filippo, Dediu Mircea, Thomas Michael, Pujol Jean-Louis, Bidoli Paolo, Molinier Olivier, Sahoo Tarini Prasad, Laack Eckart, Reck Martin, Corral Jesús, Melemed Symantha, John William, Chouaki Nadia, Zimmermann Annamaria H, Visseren-Grul Carla, Gridelli Cesare, Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial, 10.1016/s1470-2045(12)70063-3
  15. Reck Martin, von Pawel Joachim, Zatloukal Petr, Ramlau Rodryg, Gorbounova Vera, Hirsh Vera, Leighl Natasha, Mezger Jörg, Archer Venice, Moore Nicola, Manegold Christian, Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL, 10.1200/jco.2007.14.5466
  16. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., Leighl N., Mezger J., Archer V., Moore N., Manegold C., , Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), 10.1093/annonc/mdq020
  17. Sandler Alan, Gray Robert, Perry Michael C., Brahmer Julie, Schiller Joan H., Dowlati Afshin, Lilenbaum Rogerio, Johnson David H., Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer, 10.1056/nejmoa061884
  18. Shepherd Frances A., Rodrigues Pereira José, Ciuleanu Tudor, Tan Eng Huat, Hirsh Vera, Thongprasert Sumitra, Campos Daniel, Maoleekoonpiroj Savitree, Smylie Michael, Martins Renato, van Kooten Maximiliano, Dediu Mircea, Findlay Brian, Tu Dongsheng, Johnston Dianne, Bezjak Andrea, Clark Gary, Santabárbara Pedro, Seymour Lesley, Erlotinib in Previously Treated Non–Small-Cell Lung Cancer, 10.1056/nejmoa050753
  19. Hoyle Martin W, Henley William, Improved curve fits to summary survival data: application to economic evaluation of health technologies, 10.1186/1471-2288-11-139
  20. Tierney Jayne F, Stewart Lesley A, Ghersi Davina, Burdett Sarah, Sydes Matthew R, Practical methods for incorporating summary time-to-event data into meta-analysis, 10.1186/1745-6215-8-16
  21. Patel Jyoti D., Socinski Mark A., Garon Edward B., Reynolds Craig H., Spigel David R., Olsen Mark R., Hermann Robert C., Jotte Robert M., Beck Thaddeus, Richards Donald A., Guba Susan C., Liu Jingyi, Frimodt-Moller Bente, John William J., Obasaju Coleman K., Pennella Eduardo J., Bonomi Philip, Govindan Ramaswamy, PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer, 10.1200/jco.2012.47.9626
Bibliographic reference Walzer, Stefan ; Chouaid, Christos ; Lister, Johanna ; Gultyaev, Dmitry ; Vergnenegre, Alain ; et. al. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. In: Expert Review of Anticancer Therapy, Vol. 15, no.1, p. 121-128 (2015)
Permanent URL http://hdl.handle.net/2078.1/158410